Summary:
- Genentech, part of Roche (RHHBY, Financial), faces FDA rejection for expanded use of Columvi.
- Analysts set a one-year target for Roche with a projected upside of 11.55%.
- GuruFocus estimates a GF Value upside of 6.56% for Roche.
Genentech's FDA Setback
Genentech, a division of Roche (RHHBY), recently encountered a hurdle as the U.S. FDA refused its application to extend the use of its cancer drug, Columvi. The FDA's decision was based on insufficient support from the STARGLO trial, specifically for cases involving relapsed or hard-to-treat diffuse large B-cell lymphoma in combination with chemotherapy.
Wall Street Analysts' Price Forecast
According to insights from 5 financial analysts, the average one-year price target set for Roche Holding AG (RHHBY, Financial) stands at $44.70. This forecast includes a high estimate of $47.50 and a low of $43.00. The projected average price implies an upside potential of 11.55% from the current market price of $40.07. For an in-depth look at these estimates, investors can visit the Roche Holding AG (RHHBY) Forecast page.
Brokerage Recommendations
The consensus recommendation from 7 brokerage firms currently places Roche Holding AG (RHHBY, Financial) at an average rating of 2.6, which corresponds to a "Hold" status. This rating is on a scale where 1 indicates a Strong Buy and 5 represents a Sell.
GuruFocus's GF Value Estimate
On the basis of GuruFocus estimates, the projected GF Value for Roche Holding AG (RHHBY, Financial) over the next year is $42.70. This suggests a potential upside of 6.56% from its current trading price of $40.07. The GF Value is a proprietary estimate by GuruFocus, reflecting what the stock should ideally trade at. This valuation method factors in historical trading multiples, business growth trends, and anticipated future performance. Further detailed data can be explored on the Roche Holding AG (RHHBY) Summary page.
